In Reply We appreciate the opportunity to expand on our methodology, which was not possible due to limited word count in the Research Letter. In this study, we used 2 variables in the National Cancer Data Base to discern whether androgen deprivation therapy (ADT) was given as part of first-course treatment. First, RX_SUMM_HORMONE indicated whether ADT was part of first-course treatment. Also, we used DX_HORMONE_STARTED_DAYS and defined concurrent ADT as patients who initiated ADT before or on the same day as start of radiotherapy. We feel that this definition of concurrent ADT with radiotherapy is clinically accurate. Allowing ADT to start 180 days after start of radiotherapy, as Dalela and colleagues did, may have mistakenly included some patients in the analysis who did not actually have “concurrent” ADT throughout the course of radiation treatment.
Falchook AD, Basak R, Chen RC. Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer—Reply. JAMA Oncol. 2017;3(2):281. doi:10.1001/jamaoncol.2016.3974